The Board of Jagsonpal Pharmaceuticals at its meeting held on 12 March 2026 approved a proposal to buyback up to 16,00,000 fully paid-up equity shares of the company at a price of Rs 250 per equity shares (a premium of through Tender Offer method, subject to shareholders approval. This represents 2.4% of the total equity shares of the Company and 7.3% of the non-promoter shareholding of the company. The proposed buyback will be undertaken for an aggregate amount not exceeding Rs 40 crore, representing
18.4% of the company's total paid-up equity share capital and free reserves based on the latest audited financial statements as of 31 March 2025.